Is CRW undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CRW?
Other financial metrics that can be useful for relative valuation.
|What is CRW's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does CRW's PE Ratio compare to its peers?
|Company||PE||Estimated Growth||Market Cap|
EMIS EMIS Group
COG Cambridge Cognition Holdings
AMS Advanced Medical Solutions Group
Price-To-Earnings vs Peers: CRW is expensive based on its Price-To-Earnings Ratio (78.6x) compared to the peer average (41x).
Price to Earnings Ratio vs Industry
How does CRW's PE Ratio compare vs other companies in the European Healthcare Services Industry?
Price-To-Earnings vs Industry: CRW is expensive based on its Price-To-Earnings Ratio (78.6x) compared to the European Healthcare Services industry average (33.5x)
Price to Earnings Ratio vs Fair Ratio
What is CRW's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||78.6x|
|Fair PE Ratio||42.4x|
Price-To-Earnings vs Fair Ratio: CRW is expensive based on its Price-To-Earnings Ratio (78.6x) compared to the estimated Fair Price-To-Earnings Ratio (42.4x).
Share Price vs Fair Value
What is the Fair Price of CRW when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CRW (£15.6) is trading above our estimate of fair value (£10.31)
Significantly Below Fair Value: CRW is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
|Date||Share Price||Average 1Y Price Target||Dispersion||High||Low||1Y Actual price||Analysts|
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.